Latest Conference Coverage


Mike Miller, PhD

Improving Alzheimer Diagnosis With Innovative Blood-Based Biomarker Tests and BD-Tau: Mike Miller, PhD

November 11th 2024

The chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]


Social Determinants of Health and the Reasons Behind Missed Diagnosis and Misdiagnosis of Myasthenia Gravis

Social Determinants of Health and the Reasons Behind Missed Diagnosis and Misdiagnosis of Myasthenia Gravis

November 10th 2024

Judith Thompson, PharmD, MPH, CPHQ, rare disease population health strategy lead at UCB, discussed the association between social determinants of health and delayed diagnosis/misdiagnosis in myasthenia gravis.


 Takeshi Iwatsubo, MD, PhD

Early Clinical Use of Anti-Amyloid Therapy for Alzheimer Disease in Japan: Takeshi Iwatsubo, MD, PhD

November 8th 2024

The professor of neuropathology at the University of Tokyo School of Medicine talked about the latest data on lecanemab use in clinical practice for Alzheimer disease in Japan presented at CTAD 2024. [WATCH TIME: 4 minutes]


Matthew Barton, PhD

Assessing Phase 2 Data on Bepranemab’s Effect on Tau Accumulation and Cognitive Function: Matthew Barton, PhD

November 7th 2024

The head of global clinical development for immunology/bone at UCB talked about findings presented at CTAD 2024 from the phase 2 trial assessing bepranemab in Alzheimer disease. [WATCH TIME: 3 minutes]


Rebecca M. Edelmayer, PhD

Current Use and Future Potential of Blood Biomarkers for Advancing Alzheimer Diagnosis: Rebecca M. Edelmayer, PhD

November 7th 2024

The vice president of scientific engagement at the Alzheimer's Association talked about the emergence of blood biomarker tests as valuable diagnostic tools for Alzheimer disease in the clinical setting. [WATCH TIME: 5 minutes]


Phase 2 cAPPricorn Study to Assess RNA Therapeutic Mivelsiran in Cerebral Amyloid Angiopathy

Phase 2 cAPPricorn Study to Assess RNA Therapeutic Mivelsiran in Cerebral Amyloid Angiopathy

November 7th 2024

The cAPPricorn-1 Phase 2 trial will assess mivelsiran’s efficacy in CAA, focusing on reducing the annualized rate of new cerebral microbleeds over 24 months.


 Krista L. Lanctôt, PhD

Predicting Response to Cannabinoid Treatment for Agitation in Alzheimer Disease: Krista L. Lanctôt, PhD

November 6th 2024

The professor of psychiatry and pharmacology at the University of Toronto talked about results from a post hoc analysis presented at CTAD 2024 that explored synthetic cannabinoid nabilone for agitation in Alzheimer disease. [WATCH TIME: 4 minutes]


Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD

The Promise of Personalized Neurostimulation in Slowing Alzheimer Progression: Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD

November 6th 2024

A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]


NeuroVoices: Richard Nowak, MD, MS, on the MINT Trial of Inebilizumab in Myasthenia Gravis

NeuroVoices: Richard Nowak, MD, MS, on the MINT Trial of Inebilizumab in Myasthenia Gravis

November 6th 2024

The director of the myasthenia gravis clinic at Yale University discussed the therapeutic potential of inebilizumab, an FDA-approved treatment for NMOSD, in myasthenia gravis, based on data from the phase 3 MINT study.


Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MD

Addressing Treatment Gaps in Adolescents With Myasthenia Gravis: Jonathan Strober, MD

November 5th 2024

The director of the Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital provided insight on promising data from the phase 2/3 VIBRANCE-MG study assessing investigational nipocalimab in adolesents with myasthenia gravis. [WATCH TIME: 3 minutes]


SIGMAR1 Activating Agent Blarcamesine Meets Pre-Specified Efficacy in Phase 2/3 Trial of Alzheimer Disease

SIGMAR1 Activating Agent Blarcamesine Meets Pre-Specified Efficacy in Phase 2/3 Trial of Alzheimer Disease

November 5th 2024

Over a 48-week treatment period, once daily blarcamesine slowed clinical decline in patients with early-stage Alzheimer disease, with even more pronounced effects in pre-specified common SIGMAR1 wild type group.


Latest Brainshuttle AD Study Interim Data Support Continued Trontinemab Development for Alzheimer Disease

Latest Brainshuttle AD Study Interim Data Support Continued Trontinemab Development for Alzheimer Disease

November 4th 2024

At week 25 of treatment with trontinemab, patients demonstrated decreases in CSF total tau, CSF p-tau181, and CSF neurogranin.


Jessica Langbaum, PhD

Enhancing Diversity and Accessibility in Clinical Trials for Alzheimer Disease: Jessica Langbaum, PhD

November 4th 2024

The senior director of research strategy at Banner Alzheimer’s Institute talked about improving clinical trial diversity through removal of logistical barriers, creating inclusive outreach strategies, and designing trials that address the unique needs of underrepresented populations. [WATCH TIME: 5 minutes]


Alireza Atri, MD, PhD

Marking a New Era in Patient Care With Advancements in Disease-Modifying Alzheimer Treatments: Alireza Atri, MD, PhD

November 3rd 2024

The director of the Banner Sun Health Research Institute talked about how the newly approved Alzheimer treatments have shown promise in slowing clinical decline, signaling a foundational shift toward disease-modifying therapies that target core biological processes. [WATCH TIME: 5 minutes]


The High Cost of Innovation: Navigating Rising Drug Prices in Neurology

The High Cost of Innovation: Navigating Rising Drug Prices in Neurology

November 3rd 2024

Amy Tsou, MD, MSc, program director at the National Institutes of Neurological Disorders and Stroke, discussed the increasing cost of prescription drugs in the US and its impact on healthcare providers, including those who treat patients with neurologic conditions.


Alzheimer Agitation Therapy Brexpiprazole Maintains Safe Profile in Longitudinal Analysis

Alzheimer Agitation Therapy Brexpiprazole Maintains Safe Profile in Longitudinal Analysis

November 2nd 2024

Over a 24-week period, comprising both the core study and extension trial, the incidence of treatment-emergent adverse events was infrequent, with less occurring over the long-term extension.


Lars Lannfelt, MD, PhD

The Arctic Mutation, Treatment Innovations, and Early Diagnosis Imperatives in Alzheimer: Lars Lannfelt, MD, PhD

November 2nd 2024

The professor of molecular geriatrics at Uppsala University talked about the research journey that led to the development of targeted antibody therapies for Alzheimer disease and emphasized the need for early diagnosis. [WATCH TIME: 5 minutes]


 Brent Forester, MD, MSc

The Promise of Cannabinoid Therapy for Agitation in Advanced Alzheimer Disease: Brent Forester, MD, MSc

November 1st 2024

The chair of psychiatry at Tufts University School of Medicine talked about a recent study that suggested synthetic tetrahydrocannabinol could reduce agitation in patients with advanced Alzheimer disease. [WATCH TIME: 5 minutes]


Todd Feaster, PsyD

Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD

November 1st 2024

The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]


Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 Expression

Alzheimer Gene Therapy LX1001 Demonstrates Dose-Dependent Increase in APOE2 Expression

October 31st 2024

LX1001, an AAV gene therapy, was considered safe and well tolerated, with no events of amyloid-related imaging abnormalities (ARIA) observed.


Michael Woodward, MD, FRACP; Anthony Caggiano, MD, PhD

Refining Alzheimer Treatment Through Biomarker-Based Patient Selection: Michael Woodward, MD, FRACP; Anthony Caggiano, MD, PhD

October 31st 2024

The head of dementia research at Austin Health and the chief medical officer at Cognition Therapeutics talked about recently presented phase 2 findings on CT1812, an investigational medicine for patients with mild to moderate Alzheimer disease, at CTAD 2024. [WATCH TIME: 5 minutes]


Screening Experience of Phase 2 Autonomy Study Provides Insights for Anti-Tau Trials in Alzheimer Disease

Screening Experience of Phase 2 Autonomy Study Provides Insights for Anti-Tau Trials in Alzheimer Disease

October 31st 2024

In total, more than half of the screened population failed by not meeting plasma p-tau217 criteria and of the remaining, most participants were not in the intermediate tau PET range.


Howard Fillit, MD

The Role of Monoclonal Antibodies and Emerging Combination Treatments to Expand Alzheimer Therapeutics: Howard Fillit, MD

October 31st 2024

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation talked about how Alzheimer disease treatment may evolve through combination therapies, adding potential anti-tau and anti-inflammatory agents to improve patient outcomes. [WATCH TIME: 5 minutes]


Margherita Carboni, PhD

Using Biomarker Testing to Advance Alzheimer Diagnostics: Margherita Carboni, PhD

October 31st 2024

The indication lead of neurology at Roche Diagnostics International talked about the latest Alzheimer biomarkers that are aimed to transform diagnostic accuracy and accessibility as well as enhance early detection and treatment. [WATCH TIME: 5 minutes]


Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQ

Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQ

October 30th 2024

The rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]


Phase 3 TRAILRUNNER-ALZ 3 to Test Effects of IgG1 Monoclonal Antibody Remternetug in Early Alzheimer Disease

Phase 3 TRAILRUNNER-ALZ 3 to Test Effects of IgG1 Monoclonal Antibody Remternetug in Early Alzheimer Disease

October 30th 2024

The multicenter, randomized, double-blind, placebo-controlled, parallel-group, event-driven trial will use time to clinical progression, defined as an increase in Clinical Dementia Rating score, as the primary end point.

© 2025 MJH Life Sciences

All rights reserved.